VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESGO 2021 | PARP inhibitor rechallenging in ovarian cancer

Isabelle Ray-Coquard • 23 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Olaparib
Molecular Profiling

Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, talks on PARP inhibitor rechallenge which may demonstrate a benefit in patients with platinum-sensitive relapsed ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Isabelle Ray-Coquard

1:08
Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?
Isabelle Ray-Coquard • 23 Oct 2021
1:19
Testing HRD in the clinic
Isabelle Ray-Coquard • 1 Sep 2021
9:49
PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
Isabelle Ray-Coquard • 28 Sep 2019
1:16
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
Isabelle Ray-Coquard • 1 Sep 2021

Related Videos

4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:05
Investigating the ATR inhibitor elimusertib in advanced solid tumors
Timothy Yap • 13 Apr 2022
2:22
TRESR trial: Investigating an ATRi in patients with DNA damage repair loss-of-function mutant tumors
Timothy Yap • 13 Apr 2022
0:50
Combinatorial PARPi therapies in advanced endometrial cancer
Benoit You • 11 Apr 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals